Best Online Menopause and HRT Providers of 2026
Menopause care has been chronically underserved by mainstream healthcare. Telehealth-first platforms now make bioidentical estradiol, progesterone, vaginal estrogen, and adjuncts like DHEA available at significantly lower price points than legacy clinics. The NAMS 2022 position statement affirms that hormone therapy is the most effective treatment for vasomotor symptoms and is appropriate for most healthy women under 60. We compared the women's-health-focused providers in our network.
Reader-supported, we may earn a commission through links on this site. Rankings are editorially independent. Disclosure · Methodology
Hormone therapy (HT) remains the most effective treatment for vasomotor symptoms of menopause, with the NAMS 2022 position statement affirming its appropriateness for most healthy women under 60 who are within 10 years of menopause onset. The Women's Health Initiative findings that drove HT avoidance in the 2000s have since been substantially reinterpreted — the cardiovascular and breast cancer risks were specific to older women using oral conjugated equine estrogen plus medroxyprogesterone acetate, not to transdermal estradiol or micronised progesterone.
Telehealth-first menopause platforms have made bioidentical estradiol patches, gels, and sprays, micronised progesterone, vaginal estrogen, and adjuncts like DHEA and testosterone available at significantly lower price points than legacy OB/GYN practices. The best platforms employ prescribers with specific menopause medicine training (NAMS-certified or equivalent) and include follow-up consultations for symptom titration.
We compared the women's-health-focused providers in our network on formulary depth (estradiol routes, progesterone type, vaginal options), prescriber credentials, and pricing. The ranking below reflects our current editorial assessment.
The Ranking
Hone Health
Hormone optimisation platform with real biomarker testing and physician-guided protocols, for men and women.
Editor’s take: If you take hormone health seriously and you're willing to pay for biomarker testing, Hone is the most clinically credible option in this list. If you only want low-friction TRT and you're price-sensitive, Peter MD or DudeMeds will fit better.
Full review →
Women-focused telehealth combining compounded GLP-1 weight loss with HRT support.
Editor’s take: A focused women's health pick. If you only want GLP-1, you'll find cheaper; if you want both GLP-1 and HRT in one clinic, this is one of the cleanest options on the list. If you only want GLP-1 without hormonal support, a lower-cost specialist like Trimi or HealthRx will be more cost-effective. If you want both GLP-1 and HRT in one clinic, Gala Health is one of the cleanest options available.
Full review →
Lab-driven telehealth clinic combining GLP-1, TRT, BHRT, and peptide longevity protocols.
Editor’s take: A multi-protocol clinic that earns its premium when you actually use the lab-and-hormone bundle. If you only want a compounded GLP-1 and nothing else, cheaper specialists exist.
Full review →
Inner Balance
Women's telehealth clinic offering bioidentical HRT, libido support, NAD+ longevity, and prescription skincare, all founded by a board-certified women's health specialist.
Editor’s take: One of the few telehealth platforms offering a complete women's hormonal health stack. HRT, libido, longevity, and skincare. under one clinical roof. The bioidentical, naturally-derived formulations and physician-founded pedigree distinguish it from general telehealth competitors. Pricing is not disclosed upfront, which is a friction point, but HSA/FSA eligibility partially offsets cost concerns.
Full review →
Defy Medical
15-year concierge TRT and hormone optimization clinic with a 4.8/5 Trustpilot score from 3,900+ verified patients.
Editor’s take: Defy Medical's combination of clinical depth, 15-year track record, and a 4.8/5 Trustpilot score from nearly 4,000 reviews puts it among the most credible TRT providers online. The lack of upfront pricing is the main friction point, but patients who prioritize clinical quality over cost transparency consistently rate it highly.
Full review →
Henry Meds
Affordable subscription telehealth with one of the largest compounded formularies in the industry.
Editor’s take: One of the deepest compounded formularies in this list. If your goals include rare ED protocols or oral-dissolving GLP-1, Henry Meds is hard to beat. Brand-name GLP-1 buyers should look at Ro or PlushCare instead.
Full review →2026 Price Comparison. All-In Monthly Cost
Prices verified June 2026· How we verify →Published monthly price terms at the lowest listed rate and higher listed rate. Read each provider’s terms note because medication, consult, shipping, and plan-length conditions vary.
Prices are verified from public provider websites and may change. Compounded medications are from 503A pharmacies operating under personalisation exceptions. Always confirm pricing and legal status directly with the provider before purchase.
| Provider | Starting dose | Maintenance dose | Pharmacy | Trustpilot | Verified | Actions |
|---|---|---|---|---|---|---|
| $149/mo | $299/mo | 503A | 4.7 | June 2026 |
- Starting dose
- $149/mo
- Maintenance dose
- $299/mo
- Pharmacy
- 503A
- Price checked
- June 2026
All prices are all-in (consult + medication + shipping) unless noted. Prices verified June 2026. Compounded medications are not FDA-approved finished products. They are compounded under 503A personalisation exceptions. Click any provider name to read the full independent review. CTA buttons link to provider websites and may earn us a commission. How we verify prices →
Methodology
Scored on formulary depth (estradiol routes, progesterone, vaginal options), specialist focus, and clinician credentials in menopause medicine.
Online Menopause Care: What the Evidence Says
Hormone therapy for menopause has been through a long rehabilitation in the clinical literature since the 2002 WHI trial scared a generation of prescribers away from it. The current evidence picture is considerably more nuanced — and for many women, the risk-benefit calculus strongly favors treatment. Here is what the data actually says.
The Rehabilitation of Hormone Therapy
The 2002 Women's Health Initiative trial found increased risks of breast cancer, coronary heart disease, stroke, and pulmonary embolism in women taking combined estrogen-progestin therapy. That finding drove a dramatic drop in HRT prescribing. Subsequent re-analysis of the WHI data — and a large body of subsequent research — has substantially revised that picture.
The key revisions: the WHI population was older (average age 63) and many had pre-existing cardiovascular risk factors. For women who start hormone therapy within 10 years of menopause or before age 60 (the 'timing hypothesis'), cardiovascular risk is not elevated and may be reduced. Breast cancer risk with estrogen-only therapy (for women without a uterus) is not elevated and may be slightly reduced. The risk signal is primarily associated with combined estrogen-progestogen therapy in older women who start late.
What Hormone Therapy Actually Treats
Vasomotor symptoms (hot flashes, night sweats) are the primary indication, and hormone therapy is the most effective treatment available — reducing frequency and severity by 75–90% in most women. Genitourinary syndrome of menopause (vaginal dryness, dyspareunia, recurrent UTIs) responds well to local estrogen, which has minimal systemic absorption and is appropriate even for women who cannot use systemic therapy.
Sleep disruption, mood changes, and cognitive symptoms often improve with vasomotor symptom control. Bone density preservation is a well-established benefit. Hormone therapy is not FDA-approved for cardiovascular prevention, though the timing hypothesis data is encouraging.
Bioidentical vs Conventional Hormones
'Bioidentical' hormones have the same molecular structure as endogenous human hormones. FDA-approved bioidentical options include estradiol (patches, gels, sprays) and micronized progesterone (Prometrium). Compounded bioidentical hormones — custom preparations from compounding pharmacies — are not FDA-approved and lack the safety and efficacy data of the approved products.
The North American Menopause Society and the Endocrine Society both recommend FDA-approved hormone therapy over compounded preparations for most women. The marketing around compounded bioidenticals often implies superior safety or efficacy; the evidence does not support that claim.
The right menopause treatment depends on your symptom profile, your personal and family medical history, and how far you are from your last period. The clinics in our top tier above all offer individualized assessment rather than one-size-fits-all protocols.
What the Studies Actually Show
Menopausal hormone therapy (estrogen ± progestogen) is the most effective treatment for vasomotor symptoms. The risk-benefit profile depends on age and time since menopause; the figures below summarise the NAMS 2022 position statement and the Women's Health Initiative long-term follow-up.
| Endpoint | Finding |
|---|---|
| Vasomotor symptom relief (NAMS 2022 position statement)1 | Menopausal hormone therapy (estrogen ± progestogen) is the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause |
| Risk-benefit window (timing hypothesis)1 | For symptomatic women under age 60 or within 10 years of menopause onset, benefits typically outweigh risks. Risk profile shifts unfavorably when initiation is delayed beyond age 60 |
| Breast cancer risk (WHI long-term follow-up)2 | Combined estrogen-progestin therapy was associated with a small absolute increase in invasive breast cancer (~8 additional cases per 10,000 person-years); estrogen-alone arm in hysterectomized women showed no increase |
| Bone health2 | Hormone therapy reduces hip and vertebral fractures by ~30–40% in postmenopausal women; effect persists during use |
Frequently Asked Questions
- NAMS 2022 Position Statement · The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause 2022;29(7):767–794.
- WHI Long-Term Follow-Up — JAMA 2017 · Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA 2017;318(10):927–938.
RxNotebook is an editorial publication. Citations point to peer-reviewed journals, FDA labeling, and clinical society guidelines. We are not affiliated with the studies cited above. This page is for general information and is not medical advice.